Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 5/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5901807 | 0.77 | MAPK14 (0.40) | MAPK11MAPK14DRD2KDM1A | |
| SCHEMBL5741788 | 0.74 | MAPK14 (0.42) | MAPK11MAPK14DRD2KDM1A | |
| SCHEMBL5757020 | 0.73 | CYP11B2 (0.38) | MAPK11MAPK14BRD4CREBBP | |
| SCHEMBL5740316 | 0.70 | MAPK14 (0.39) | MAPK11MAPK14DRD2 | |
| SCHEMBL5741723 | 0.65 | GSK3B (0.54) | — | |
| SCHEMBL6364470 | 0.64 | ADORA2A (0.42) | MAPK11MAPK14KDM1A | |
| SCHEMBL2077345 | 0.56 | QDPR (0.50) | MAPK11MAPK14 | |
| SCHEMBL27217308 | 0.56 | GAA (0.40) | MAPK11MAPK14DRD2BRD4CREBBP | |
| SCHEMBL19995445 | 0.54 | TNKS (0.45) | MAPK11MAPK14 | |
| SCHEMBL20908872 | 0.53 | QDPR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654250-A1 | SUBSTITUTED PYRIDONES AND PYRIMIDINONES WITH ANTIINFLAMMATORY PROPERTIES | AMGEN INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005012286-A1 | SUBSTITUTED PYRIDONES AND PYRIMIDINONES WITH ANTIINFLAMMATORY PROPERTIES | AMGEN INC. (US) | 2005-02-10 | — | — | WO | disclosed |